The overall survival (OS) data for the TROP2 ADC drug DS-1062 (datopotamab deruxtecan), developed by AstraZeneca in collaboration with Daiichi Sankyo, did not meet statistical assumptions but was numerically beneficial to the drug in clinical trials. Although the Tropion-Lung01 clinical study did not reach the primary OS endpoint, the application for marketing was supported by reaching the primary study endpoint in progression-free survival (PFS). Currently, the drug's marketing application is being reviewed by global regulators such as the US and the European Union. Industry insiders believe that although OS is the “gold standard” for drug review, the positive results of PFS may have a positive impact on the review. (every time)